Pharmacology Watch
RSSArticles
-
New Recommendations for Bisphosphonate Therapy
For women who are not at high risk after 3-5 years of bisphosphonate therapy, a drug holiday of 2-3 years may be considered.
-
Study: No Link Between Dementia, Benzodiazepine Use
New research upends previous beliefs.
-
Updated Antithrombotic Therapy Guidelines Released
The guideline contains some significant changes from the previous CHEST guidelines.
-
FDA Actions
In this section: The FDA may soon recommend against using codeine for pain and cough in children underage children; vitamin D supplementation may not prevent elderly falls after all; agency approves insulin glargine for the treatment of diabetes; and mepolizumab for maintenance treatment of asthma when used with other asthma medications receives approval.
-
Comparing Type 2 Diabetes Drug Therapies
A new evidence review compares the weekly glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes.
-
Report: Opioid Overdose Deaths Up 200% Since 2000
Death by prescription drugs is out of control.
-
USPSTF Modifies Statin Treatment Guideline
The guideline builds on the “risk-based” statin treatment recommendations rather than the previous “treat-to-target” method of treating to a specific LDL cholesterol.
-
FDA Actions
In this section: the FDA approves a nasal spray to cease or reverse opioid overdose, recommends stronger warning labels on fluoroquinolones, and greenlights a once-daily, fixed-dose combination pill for treating HIV-1 infection.
-
Breakthrough in Hepatitis C Treatment?
New drug shows promise in recent trial.
-
AMA: Ban Direct-to-Consumer Ads
The American Medical Association is concerned the billions of dollars spent on drug and device ads is “driving demand for expensive treatments despite the clinical effectiveness of less costly alternatives” and is “fueling escalating drug prices.”